How does Besponsa work to treat acute lymphoblastic leukemia (ALL)?
Medically reviewed by Drugs.com. Last updated on Sep 30, 2020.
Besponsa works by binding to B-cell ALL cancer cells that express the CD22 antigen and blocking the growth of cancerous cells.
Besponsa (inotuzumab ozogamicin), from Pfizer, is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in adults.
Related Medical Questions
- What is the lifetime or cumulative dose for Adriamycin?
- Is Sprycel a chemotherapy drug?
- Gleevec vs Sprycel vs Tasigna - how do they compare?
- Is Tasigna a form of chemotherapy?
- What to avoid when taking Gleevec?
- How long does it take Sprycel (dasatinib) to start working?
- How much does Blincyto (blinatumomab) cost?
- How does Gleevec (imatinib) work?
- Is there a generic for Gleevec?
- Is Blincyto (blinatumomab) chemotherapy?
- What is the cost of Kymriah?
- How is Blincyto taken / administered?
- Can I take Gleevec while pregnant?
- How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?
- How is Kymriah administered?
- Besponsa Information for Consumers
- Besponsa Information for Healthcare Professionals (includes dosage details)
- Side Effects of Besponsa (detailed)